Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katja C Weisel

Showing results (51-60 of 93) with videos related to

Pageof 10
Sort By:
Blood Cancer Journal|April 1, 2026
Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United StatesShaji Kumar, Katja C Weisel, Paul Spin, et al.
Leukemia|July 1, 2018
Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myelomaElias K Mai, Thomas Hielscher, Uta Bertsch, et al.
Leukemia|November 4, 2021
Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trialLisa B Leypoldt, Britta Besemer, Anne Marie Asemissen, et al.
Haematologica|April 16, 2016
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myelomaKatja C Weisel, Meletios A Dimopoulos, Philippe Moreau, et al.
Blood Cancer Journal|February 15, 2020
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myelomaMeletios A Dimopoulos, Andrzej J Jakubowiak, Philip L McCarthy, et al.
Hemasphere|November 21, 2024
Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trialElias K Mai, Axel Nogai, Henk M Lokhorst, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Mutagenic impact and evolutionary influence of radiotherapy in hematologic malignanciesBenjamin Diamond, Dhanvantri Chahar, Michael D Jain, et al.
Haematologica|July 11, 2015
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myelomaJesus F San Miguel, Katja C Weisel, Kevin W Song, et al.
Cancers|August 23, 2020
Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD AssessmentKatharina Kriegsmann, Michael Hundemer, Nicole Hofmeister-Mielke, et al.
Blood|June 12, 2025
Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRSTMaximilian Merz, Nico Gagelmann, Samih Smaili, et al.
Pageof 10

Showing results (51-60 of 93) with videos related to

Sort By:
Pageof 10
Blood Cancer Journal|April 1, 2026
Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United StatesShaji Kumar, Katja C Weisel, Paul Spin, et al.
Leukemia|July 1, 2018
Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myelomaElias K Mai, Thomas Hielscher, Uta Bertsch, et al.
Leukemia|November 4, 2021
Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trialLisa B Leypoldt, Britta Besemer, Anne Marie Asemissen, et al.
Haematologica|April 16, 2016
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myelomaKatja C Weisel, Meletios A Dimopoulos, Philippe Moreau, et al.
Blood Cancer Journal|February 15, 2020
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myelomaMeletios A Dimopoulos, Andrzej J Jakubowiak, Philip L McCarthy, et al.
Hemasphere|November 21, 2024
Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trialElias K Mai, Axel Nogai, Henk M Lokhorst, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Mutagenic impact and evolutionary influence of radiotherapy in hematologic malignanciesBenjamin Diamond, Dhanvantri Chahar, Michael D Jain, et al.
Haematologica|July 11, 2015
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myelomaJesus F San Miguel, Katja C Weisel, Kevin W Song, et al.
Cancers|August 23, 2020
Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD AssessmentKatharina Kriegsmann, Michael Hundemer, Nicole Hofmeister-Mielke, et al.
Blood|June 12, 2025
Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRSTMaximilian Merz, Nico Gagelmann, Samih Smaili, et al.
Pageof 10